Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Clinical Trial ID NCT01239316

PubWeight™ 14.79^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01239316

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	G protein-coupled receptors: novel targets for drug discovery in cancer.	Nat Rev Drug Discov	2011	3.31
2	Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.	Nat Rev Clin Oncol	2015	2.02
3	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.	J Clin Oncol	2015	1.72
4	Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting.	Sarcoma	2012	0.99
5	The rationale for targeted therapies in medulloblastoma.	Neuro Oncol	2013	0.92
6	Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.	Cancers (Basel)	2016	0.91
7	Molecular profiling of childhood cancer: Biomarkers and novel therapies.	BBA Clin	2014	0.86
8	Targeted treatment for sonic hedgehog-dependent medulloblastoma.	Neuro Oncol	2014	0.83
9	MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.	FASEB J	2015	0.80
10	Advances in paediatric cancer treatment.	Transl Pediatr	2014	0.76
11	Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.	Clin Pharmacokinet	2016	0.76
12	Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma.	J Exp Pharmacol	2012	0.75
13	Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.	J Exp Pharmacol	2012	0.75